Abstract:Precision medicine relies on the idea that, for a particular targeted agent, only a subpopulation of patients is sensitive to it and thus may benefit from it therapeutically. In practice, it is often assumed based on preclinical data that a treatment-sensitive subpopulation is known, and moreover that the agent is substantively efficacious in that subpopulation. Due to important differences between preclinical settings and human biology, however, data from patients treated with a new targeted agent often show that one or both of these assumptions are false. This paper provides a Bayesian randomized group sequential enrichment design that compares an experimental treatment to a control based on survival time and uses early response as an ancillary outcome to assist with adaptive variable selection and enrichment. Initially, the design enrolls patients under broad eligibility criteria. At each interim decision, submodels for regression of response and survival time on a baseline covariate vector and treatment are fit; variable selection is used to identify a covariate subvector that characterizes treatment-sensitive patients and determines a personalized benefit index, and comparative superiority and futility decisions are made. Enrollment of each cohort is restricted to the most recent adaptively identified treatment-sensitive patients. Group sequential decision cutoffs are calibrated to control overall type I error and account for the adaptive enrollment restriction. The design provides a basis for precision medicine by identifying a treatment-sensitive subpopulation, if it exists, and determining whether the experimental treatment is superior to the control in that subpopulation. A simulation study shows that the proposed design reliably identifies a sensitive subpopulation, yields much higher generalized power compared to several existing enrichment designs and a conventional all-comers group sequential design, and is robust.

Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers

Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkers

Optimal Marker-Strategy Clinical Trial Design to Detect Predictive Markers for Targeted Therapy

Two-Stage Marker-Stratified Clinical Trial Design in the Presence of Biomarker Misclassification

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Optimal predictive probability designs for randomized biomarker-guided oncology trials

Biomarker-Guided Adaptive Enrichment Design with Threshold Detection for Clinical Trials with Time-to-Event Outcome

Optimal Sequential Enrichment Designs for Phase II Clinical Trials.

Two-Stage Adaptive Enrichment Designs with Survival Outcomes and Adjustment for Misclassification in Predictive Biomarkers

Hybrid Design Evaluating New Biomarkers when There is an Existing Screening Test

Two‐stage stratified designs with survival outcomes and adjustment for misclassification in predictive biomarkers

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Subgroup-Based Adaptive (SUBA) Designs for Multi-arm Biomarker Trials

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

Biomarker-Driven Oncology Trial Design and Subgroup Characterization: Challenges and Potential Solutions

Adaptive Promising Zone Design for Cancer Immunotherapy with Heterogeneous Delayed Treatment Effect

Optimizing Trial Designs for Targeted Therapies

BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity

Lessons Learned from Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

Statistical Inference of Adaptive Randomized Clinical Trials for Personalized Medicine

A Bayesian Decision-Theoretic Design for Simultaneous Biomarker-Based Subgroup Selection and Efficacy Evaluation